Fig. 4: TME composition features of FeSighigh and FeSiglow cohort. | Communications Biology

Fig. 4: TME composition features of FeSighigh and FeSiglow cohort.

From: Ferroptosis-related gene signature for predicting prognosis and identifying potential therapeutic drug in EGFR wild-type lung adenocarcinoma

Fig. 4

a Correlation analysis of FeSig and 20 TME cell signatures score. b Heatmap of fibroblast-related genes in TCGA-EGFRWT LUAD patients. c HE staining of FeSighigh and FeSiglow samples in TCGA-EGFRWT LUAD, scale bar: 500 μm. d Immunofluorescence staining of α-SMA (green) in FeSighigh and FeSiglow patients. Scale bar: 20 μm. e Quantitative analysis of mean percentage difference of α-SMA between FeSighigh (n = 31) and FeSiglow (n = 30) patients (Wilcoxon test). Error bars depict as mean ± SD.

Back to article page